Medical Week Daily

Medical news today: Tuesday, November 10, 2026

FDA approves asundexian for selected stroke survivors; early gene-editing lipid data emerge; preliminary AI echocardiogram study reports faster review

Get tomorrow's issue in your inbox.

  1. 01

    FDA approves asundexian, the first US-approved Factor XIa inhibitor for selected patients after stroke or high-risk TIA

    Source: US FDA

    The FDA announced on November 9 that it had approved Sunharbo (asundexian) 50 mg once daily with antiplatelet therapy to reduce stroke risk in adults after a recent mild-to-moderate non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack. The decision was supported by the phase 3 OCEANIC-STROKE trial of 12,327 adults; the FDA reports a 26% reduction in ischaemic stroke versus placebo over a median 14.2 months. Overall major bleeding was similar between groups, but was higher with asundexian in patients older than 75 and during the first 90 days; gastrointestinal bleeding was more common and diarrhoea was the most frequent adverse reaction. The drug is not approved for stroke prevention in atrial fibrillation.

    Why it mattersThis is a regulatory milestone for Factor XIa inhibition, but the indication is specific. Prescribers and safety teams need to attend to bleeding patterns, drug interactions, hepatic restrictions and peri-procedural withholding instructions in the FDA release rather than extrapolating the approval to other stroke mechanisms or atrial fibrillation. More on Approvals & regulatory →

  2. 02

    Phase 1b CTX310 gene-editing study reports large triglyceride reductions in 10 adults

    Source: Cleveland Clinic

    Cleveland Clinic reported on November 9 that a phase 1b study of CTX310, an intravenous CRISPR-Cas9 therapy targeting ANGPTL3, included 10 adults with severe hypertriglyceridaemia. Thirty days after a single infusion, average triglycerides were 63% lower, with reductions up to 85%; ANGPTL3 levels fell by more than 65%. The investigators reported no serious treatment-related adverse effects in this small early study. The results were presented at the American Heart Association Scientific Sessions and do not establish long-term durability or cardiovascular benefit. The study was funded by CRISPR Therapeutics.

    Why it mattersThe findings are an early proof-of-concept for gene editing in severe lipid disorders, not evidence of an established treatment. Longer follow-up is needed to assess durability, delayed risks, dose selection and whether biomarker changes translate into fewer pancreatitis or cardiovascular events. More on Drug & device safety →

  3. 03

    AI-assisted echocardiogram drafts cut cardiologists’ review time by about 46% in a preliminary trial

    Source: American Heart Association

    The American Heart Association reported on November 9 that a randomized study compared AI-generated preliminary reports with sonographer- and cardiologist-prepared drafts for 1,200 echocardiograms from 21 Kaiser Permanente Northern California medical centres. Cardiologists made substantial changes to 50.6% of AI drafts versus 49.7% of human-prepared drafts, meeting the study's non-inferiority criterion. Average review and finalisation time was 4.6 minutes with AI drafts versus 8.5 minutes without them, a reduction of about 46%. The results were presented as a late-breaking conference abstract and have not yet been peer-reviewed.

    Why it mattersThe study suggests AI may reduce reporting workload while keeping a cardiologist responsible for the final interpretation. It did not test long-term patient outcomes, and the authors say larger real-world evaluations are needed before assuming the time savings or accuracy will generalise. More on Journal papers →

New here? How to read this digest
Each story links to its original source. "Why it matters" explains what it means for you in plain language. This is news, not medical advice: talk to your doctor about your own care. Browse all topics or the archive.

More recent digests

Free daily email

The day's approvals, safety signals and trials, in five minutes.

Join the list with just your email. You can also follow the RSS feed.

Free, one field, no spam. We only use your address to send Medical Week Daily and never sell it. Ask to be removed any time via the contact page. See the privacy note.

For information and education only. Not medical advice. Medical Week Daily summarizes published health news in plain language for general readers. It does not replace advice from your doctor, product labeling or regulatory documents. Always consult a qualified healthcare professional about your own care, and check the original source. Full medical disclaimer